Overview

• Delhi barred the sale and distribution of Coldrif after declaring batch SR-13 not of standard quality, joining states such as Madhya Pradesh, Tamil Nadu, Punjab and West Bengal in imposing restrictions.
• Fresh failures from the same batch were reported in Madhya Pradesh, with the Jabalpur result bringing the count of failed samples to four and official analyses showing roughly 46% to 48.6% w/v diethylene glycol.
• Sresan Pharmaceutical owner G. Ranganathan was arrested in Chennai and remanded to 10 days’ police custody as a Special Investigation Team examines manufacturing practices, suppliers and distribution.
• The Supreme Court dismissed a public interest plea seeking a CBI probe into the deaths, with the bench noting that state authorities are already pursuing investigations.
• Regulators ordered wider surveillance and testing, with the DCGI directing checks of raw materials and finished products and states such as West Bengal dispatching large numbers of cough syrup samples for analysis while political and medical groups demanded accountability.